Wilms Tumor (Nephroblastoma), Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Author:

Balis Frank1,Green Daniel M.2,Anderson Clarke3,Cook Shelly4,Dhillon Jasreman5,Gow Kenneth6,Hiniker Susan7,Jasty-Rao Rama8,Lin Chi9,Lovvorn Harold10,MacEwan Iain11,Martinez-Agosto Julian12,Mullen Elizabeth13,Murphy Erin S.14,Ranalli Mark15,Rhee Daniel16,Rokitka Denise17,Tracy Elisabeth (Lisa)18,Vern-Gross Tamara19,Walsh Michael F.20,Walz Amy21,Wickiser Jonathan22,Zapala Matthew23,Berardi Ryan A.24,Hughes Miranda24

Affiliation:

1. 1Abramson Cancer Center at the University of Pennsylvania;

2. 2St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center;

3. 3City of Hope National Medical Center;

4. 4University of Wisconsin Carbone Cancer Center;

5. 5Moffitt Cancer Center;

6. 6Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance;

7. 7Stanford Cancer Institute;

8. 8University of Michigan Rogel Cancer Center;

9. 9Fred & Pamela Buffett Cancer Center;

10. 10Vanderbilt-Ingram Cancer Center;

11. 11UC San Diego Moores Cancer Center;

12. 12UCLA Jonsson Comprehensive Cancer Center;

13. 13Dana-Farber/Brigham and Women’s Cancer Center;

14. 14Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute;

15. 15The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute;

16. 16The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;

17. 17Roswell Park Comprehensive Cancer Center;

18. 18Duke Cancer Institute;

19. 19Mayo Clinic Cancer Center;

20. 20Memorial Sloan Kettering Cancer Center;

21. 21Robert H. Lurie Comprehensive Cancer Center of Northwestern University;

22. 22UT Southwestern Simmons Comprehensive Cancer Center;

23. 23UCSF Helen Diller Family Comprehensive Cancer Center; and

24. 24National Comprehensive Cancer Network.

Abstract

The NCCN Guidelines for Wilms Tumor focus on the screening, diagnosis, staging, treatment, and management of Wilms tumor (WT, also known as nephroblastoma). WT is the most common primary renal tumor in children. Five-year survival is more than 90% for children with all stages of favorable histology WT who receive appropriate treatment. All patients with WT should be managed by a multidisciplinary team with experience in managing renal tumors; consulting a pediatric oncologist is strongly encouraged. Treatment of WT includes surgery, neoadjuvant or adjuvant chemotherapy, and radiation therapy (RT) if needed. Careful use of available therapies is necessary to maximize cure and minimize long-term toxicities. This article discusses the NCCN Guidelines recommendations for favorable histology WT.

Publisher

Harborside Press, LLC

Subject

Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3